[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"dilated-cardiomyopathy\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:dilated-cardiomyopathy":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,18,0,[8,42,72,105,127,179,211,236,284,309,338,372,398,423,445,469,492,515],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":27,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100551784","phase-1-a-phase-1-open-label-study-of-the-safety-of-intravenous-allogeneic-neonatal-mesenchymal-cells-nmscs-in-young-adult-1a-and-pediatric-1b-patients-with-dilated-cardiomyopathy-dcm-100551784",false,"NCT06464588","A Phase 1 Open-Label Study of the Safety of Intravenous Allogeneic Neonatal Mesenchymal Cells (nMSCs) in Young Adult (1A) and Pediatric (1B) Patients With Dilated Cardiomyopathy (DCM)","Inclusion Criteria\n\n* Phase 1A: Age greater than or equal to 16 years and less than 40 years (≥16 years, \\\u003C40 years).\n* Phase 1B: Age greater than or equal to 4 years and less than 16 years (≥4 years, \\\u003C16 years)\n* Subjects must be able to sign their own consent for Phase 1A of the study.\n* Diagnosis of dilated cardiomyopathy (DCM) defined as\n\n  * Any Congenital Cardiac Malformation with systemic ventricular systolic dysfunction; Idiopathic Cardiomyopathy; Familial\u002FInherited and\u002For Genetic Cardiomyopathy; History of Myocarditis; Acquired (Chemotherapy, Iatrogenic, Infection, Rheumatic, Nutritional); Ischemic (e.g. Kawasaki Disease, post-operative); Left ventricular noncompaction; Coronary Artery Disease\n  * Left ventricular ejection fraction less than or equal to 45% documented by two-dimensional echocardiogram or cardiac MRI within the prior six months.\n  * Left ventricular dilation as defined by echocardiography left ventricular and end-diastolic dimension Z score \\> +2.0\n  * Biventricular physiology with systemic left ventricle\n* Must receive guideline directed heart failure as defined by the American Heart Association, American College of Cardiology, and Heart Failure Society of America 118\n* Have been unresponsive or poorly responsive to at least 3 months of maximum guideline directed treatments.\n\nExclusion Criteria\n\n* Listed for heart transplantation (as UNOS status 1A) or hospitalized while waiting for transplant (while on inotropes or with ventricular assist device)\n* Cardiovascular surgery of percutaneous intervention to palliate or correct congenital cardiovascular malformations within 3 months of the screening visit. Patients anticipated to undergo corrective heart surgery during the 12 months after entry into Part 1A\u002F1B.\n* Previous heart transplant recipient\n* Unoperated primary obstructive or severe regurgitant valve (aortic, pulmonary, mitral or tricuspid) disease, or significant systemic ventricular outflow obstruction or aortic arch obstruction anticipated to require surgical or transcatheter intervention within 6 months.\n* Restrictive or hypertrophic cardiomyopathy\n* Cardiogenic shock\n* Currently on extracorporeal membrane oxygenation support\n* Ventricular assist device support\n* Lethal, uncontrollable arrhythmia defined as an arrhythmia resulting in hemodynamic instability requiring need for defibrillation, continuous intravenous anti-arrhythmic medication or mechanical circulatory support\n* Patients with persistent atrial fibrillation requiring specific pharmacotherapy\n* Amyloidosis\n* Ischemic dilated cardiomyopathy\n* Clinical history of malignant neoplasm within 5 years (with the exception of curatively treated basal cell carcinoma, squamous cell carcinoma, or cervical carcinoma)\n* Serious neurologic disorder including loss of vision, stroke, or paralysis\n* High-grade pulmonary embolism requiring interventional catheter procedure or pulmonary hypertension requiring use of pulmonary vasodilators including phosphodiesterase inhibitor or nitric oxide\n* High-grade renal failure \\[eGFR\\\u003C45\\] mL\u002Fmin\u002F1.73 m2 - serum potassium \\>5.3 mmol\u002FL\n* Multiple organ failure\n* Non-cardiac condition that limits life span for \\\u003C1 year\n* Uncontrolled diabetes (HbA1c \\>9%) at screening\n* Active infection (including endocarditis) requiring pharmacotherapy\n* Sepsis\n* Active hemorrhagic disease (e.g., gastrointestinal bleeding, injury)\n* History of cardiac transplantation\n* Immune system-altering medications, or immunosuppressive therapy at the time of enrolment or within the prior 12 weeks\n* Dystrophin-associated cardiomyopathy confirmed by standard cardiomyopathy panel testing\n* Confirmed myocarditis at time of screening\n* Elevated LFTs greater than 2 times upper limit of normal at time of consent\n* Elevated WBC greater than upper limit of normal as defined by local lab at time of consent\n* Presence of HLA antibodies specific for therapeutic study product\n* History of noncompliance, alcohol abuse, recreational drug use, or incarceration within the last year\n* Currently pregnant or breastfeeding\n* Unsafe\u002Funfeasible to enroll due to PI\u002Fdesignee discretion","ALL","4 Years","40 Years",{"count":19,"type":20},36,"ESTIMATED","INTERVENTIONAL",[23],"PHASE1","This is a Phase 1 study to determine the safety and efficacy of allogeneic neonatal mesenchymal stromal cells (nMSCs) for the treatment of Dilated Cardiomyopathy. The purpose of the study is to help doctors and scientists learn if allogeneic neonatal mesenchymal stromal cells (nMSCs) infusions are a safe and effective way to improve cardiac function and left ventricular ejection fraction.",[26],"Dilated Cardiomyopathy",[26,28],"Neonatal Mesenchymal Cells (nMSCs)","RECRUITING","2026-06-23",{"date":32,"type":33},"2026-06-26","ACTUAL",{"date":35,"type":33},"2025-07-14",{"date":37,"type":20},"2027-07",{"name":39,"class":40},"Emory University","OTHER",5,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":48,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":15,"minAge":50,"maxAge":51,"enrollmentInfo":52,"targetDuration":4,"studyType":21,"phases":54,"briefSummary":55,"conditions":56,"keywords":57,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":71},"100611478","phase-1-a-study-of-azd4063-in-pln-r14del-dilated-cardiomyopathy-100611478","NCT07241104","A Study of AZD4063 in PLN R14del Dilated Cardiomyopathy","A Phase I First-in-human Study to Investigate Safety, Tolerability, and Pharmacokinetics of AZD4063 in Adults With Phospholamban R14del Dilated Cardiomyopathy","PULSE","Inclusion Criteria:\n\n* Participants must be 18 to 80 years of age inclusive, at the time of Screening\n* Participants with pre-existing positive screening for R14 del PLN mutation\n* Participants with screening Left ventricular eject fraction ≤ 45% as assessed by echocardiography\n* Participants with New York Heart Association (NYHA) function class I-III\n* Participants on stable medical therapy for at least 6 weeks prior to Screening and during the Screening period, with no significant improvement in heart failure\n* Participants with implantable cardioverter-defibrillator (ICD) or Cardiac resynchronization therapy device (CRT-D)\n* Participants with Body mass index (BMI) within the range 18-35 kg\u002Fm2\n* Females of childbearing potential must not be lactating, and if heterosexually active must agree to use an approved method of highly effective contraception\n* All females must have a negative pregnancy test at the Screening Visit.\n\nExclusion Criteria:\n\n* Participants with positive hepatitis C antibody, hepatitis B virus surface antigen or hepatitis B virus core antibody\n* Known to have tested positive for Human immunodeficiency virus (HIV)\n* Any known genetic mutation associated with hereditary electrical or structural disease\n* Congenital long QT syndrome\n* QTcF \\\u003C 350 ms\n* Known Short QT syndrome (SQTS) or family history of SQTS\n* Catecholaminergic polymorphic ventricular tachycardia (CPVT as calcium ion channelopathy) and recent hospitalization for heart failure or significant ventricular arrhythmia within 3 months\n* Participants with sustained ventricular arrhythmia requiring treatment and considered clinically not stable by the Investigator\n* History of subendocardial Late Gadolinium Enhancement (LGE) suggestive of previous myocardial infarction and\u002For significant coronary artery disease (50% \\> stenosis in one major epicardial coronary artery or need for previous percutaneous coronary intervention or coronary artery bypass grafting)\n* Routinely scheduled outpatient intravenous infusions for heart failure\n* Uncontrolled hypertension\n* Significant primary valvular disease\n* Congenital heart disease\n* Left ventricular wall thickness of \\> 13 mm or with any relative with hypertrophic cardiomyopathy (HCM)\n* Recent acute presentation of myocarditis\n* Restrictive or peripartum cardiomyopathy; infiltrative disorders (sarcoidosis)\n* Alcohol consumption in excess\n* Any laboratory values with the following deviations:\n\n  1. Alanine Transaminase \\>2 upper normal limit (ULN)\n  2. Aspartate Transaminase \\>2 ULN\n  3. Total bilirubin \\> 2 x ULN\n  4. Estimated GFR \\\u003C 30 mL\u002Fmin\u002F1.73 m2\n  5. Hemoglobin \\\u003C10g\u002FdL\n* Any vital sign values with the following deviations at Screening\n\n  1. Systolic blood pressure \\> 160 mmHg\n  2. Diastolic blood pressure \\> 100 mmHg\n  3. Pulse rate \\> 100 beats per minute\n* Toxin exposure, systemic disease known to cause Dilated Cardiomyopathy (DCM)\n* History of severe allergy\u002Fhypersensitivity or ongoing clinically important allergy\u002Fhypersensitivity\n* Any history of cardiotoxic drug exposure with documented cardiomyopathy\n* Noncardiac condition that limits expected lifespan to less than 1 year\n* Participation in another clinical study with a study intervention administered in the last 3 months\n* Participants with a known hypersensitivity to AZD4063\n* Participants who are part of a gene therapy trial","18 Years","80 Years",{"count":53,"type":20},31,[23],"The purpose of the study is to assess the safety, tolerability and the pharmacokinetics (PK) of AZD4063 after single and multiple dose administration in participants with phospholamban (PLN) R14del dilated cardiomyopathy.",[26],[58,59,60],"Single Ascending Dose","Multiple Ascending Dose","Phospholamban","2026-06-17",{"date":63,"type":33},"2026-06-18",{"date":65,"type":33},"2025-12-01",{"date":67,"type":20},"2027-11-22",{"name":69,"class":70},"AstraZeneca","INDUSTRY",4,{"id":73,"slug":74,"hasResults":11,"nctId":75,"briefTitle":76,"officialTitle":76,"acronym":4,"eligibilityCriteria":77,"healthyVolunteers":11,"sex":15,"minAge":4,"maxAge":4,"enrollmentInfo":78,"targetDuration":4,"studyType":80,"phases":4,"briefSummary":81,"conditions":82,"keywords":88,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":96,"startDateStruct":98,"completionDateStruct":100,"leadSponsor":102,"locationsCount":104},"100242269","pediatric-cardiomyopathy-mutation-analysis-100242269","NCT02432092","Pediatric Cardiomyopathy Mutation Analysis","Inclusion Criteria:\n\n* Subjects with cardiomyopathy\n* Family members of subjects with cardiomyopathy\n\nExclusion Criteria:\n\n* Subjects without cardiomyopathy\n* Family members of subjects without cardiomyopathy",{"count":79,"type":20},300,"OBSERVATIONAL","The goal of this protocol is to obtain information from individuals with cardiomyopathy and from their families in order to elucidate the molecular genetics of this disorder. This will provide the basis for future genetic counseling as well as contribute to elucidating the biology of normal and abnormal cardiac function.",[83,26,84,85,86,87],"Cardiomyopathies","Hypertrophic Cardiomyopathy","Restrictive Cardiomyopathy","Arrhythmogenic Right Ventricular Cardiomyopathy","Left Ventricular Non-compaction Cardiomyopathy",[89,90,91,92,93,94,95],"Cardiomegaly","Cardiovascular Diseases","Heart Diseases","Systolic dysfunction","Diastolic dysfunction","Ventricular hypertrophy","Heart failure",{"date":97,"type":33},"2026-06-22",{"date":99,"type":4},"2014-04",{"date":101,"type":20},"2030-12-31",{"name":103,"class":40},"Indiana University",1,{"id":106,"slug":107,"hasResults":11,"nctId":108,"briefTitle":109,"officialTitle":110,"acronym":4,"eligibilityCriteria":111,"healthyVolunteers":11,"sex":15,"minAge":50,"maxAge":4,"enrollmentInfo":112,"targetDuration":4,"studyType":80,"phases":4,"briefSummary":114,"conditions":115,"keywords":116,"overallStatus":118,"whyStopped":4,"lastUpdateSubmitDate":119,"lastUpdatePostDateStruct":120,"startDateStruct":122,"completionDateStruct":124,"leadSponsor":126,"locationsCount":104},"100642968","observational-study-of-natural-history-of-bag3-gene-mutation-associated-dilated-cardiomyopathy-in-chinese-adults-100642968","NCT07646600","Observational Study of Natural History of BAG3 Gene Mutation-Associated Dilated Cardiomyopathy in Chinese Adults","Natural History of BAG3 Gene Mutation-Associated Dilated Cardiomyopathy in Chinese Adults: A Multicentre, Prospective, Observational Cohort Study","Inclusion Criteria:\n\n* Participants must meet all of the following criteria to be eligible for inclusion:\n\n  1. Age ≥18 years at screening, male or female;\n  2. Presence of a BAG3 pathogenic or likely pathogenic mutation interpreted according to the American College of Medical Genetics and Genomics (ACMG) guidelines;\n  3. Heart failure (HF) Stage B or C, New York Heart Association (NYHA) functional class I-III;\n  4. LVEF ≤50%. If LVEF is 45%-50% and the participant is classified as Stage B heart failure or NYHA Class I, N-terminal pro-B-type natriuretic peptide (NT-proBNP) must be ≥300 pg\u002FmL. LVEF measurement must be based on echocardiography or cardiac magnetic resonance results within the past 12 months;\n  5. Willing and able to comply with all scheduled visits, laboratory tests, and other study procedures;\n  6. Capable of providing signed informed consent, including compliance with the requirements and restrictions listed in the informed consent form and this protocol.\n\nExclusion Criteria:\n\n* Participants meeting any of the following criteria will be excluded:\n\n  1. Acute decompensated heart failure within 1 month prior to enrollment;\n  2. Any of the following within 3 months prior to screening:\n\n     * Myocardial infarction\n     * Cardiac surgical procedures (excluding pacemaker\u002Fimplantable cardioverter defibrillator\u002Fcardiac resynchronization therapy implantation)\n     * Implantable cardioverter defibrillator (ICD) implantation\n     * Acute coronary syndrome\n     * Hospitalization for cardiac arrhythmia\n  3. History of heart transplantation;\n  4. Estimated glomerular filtration rate (eGFR) \\\u003C30 mL\u002Fmin\u002F1.73 m² (calculated using the Chronic Kidney Disease Epidemiology Collaboration formula);\n  5. Active malignancy or malignancy diagnosed within 3 years prior to screening, except for:\n\n     * Surgically cured in situ malignancies\n     * Surgically cured early-stage cancers (including breast, prostate, skin \\[basal cell carcinoma, squamous cell carcinoma\\], thyroid, or cervical cancer)\n     * Other early-stage malignancies with an expected 2-year recurrence rate ≤20%, approved by the Medical Monitor\n  6. Non-cardiac condition limiting life expectancy to \\\u003C1 year;\n  7. Presence of any of the following cardiac conditions:\n\n     * Other forms of cardiomyopathy contributing to heart failure (e.g., inflammatory or infiltrative cardiomyopathy)\n     * Clinically significant cardiac anatomic abnormalities (e.g., left ventricular aneurysm)\n     * Significant coronary artery disease (e.g., prior revascularization, exercise-induced angina)\n     * Uncorrected, hemodynamically significant (moderate to severe) primary structural valvular disease not due to heart failure (investigator's judgment)\n  8. Any severe concurrent disease (e.g., active systemic infection) that, in the investigator's judgment, would make the participant unsuitable for study participation;\n  9. Any medical or psychiatric condition that may increase study risk, including:\n\n     * Active or recent (within 1 year) suicidal ideation\u002Fbehavior\n     * Laboratory abnormalities\n     * Other conditions deemed unsuitable by the investigator\n  10. Administration of any investigational drug within 30 days prior to screening;\n  11. Prior gene or cell therapy treatment;\n  12. Anticipated need for cardiac transplantation, left ventricular assist device implantation, or other cardiac surgery within the next 3 months (investigator's assessment);\n  13. More than 3 first-degree relatives from the same family enrolled concurrently (excluding the participant).",{"count":113,"type":20},10,"This is a multicentre, prospective cohort study designed to elucidate the natural history of dilated cardiomyopathy (DCM) associated with specific gene mutations in Chinese patients. By establishing a cohort of patients with inherited cardiomyopathy, the study will collect comprehensive data, including demographic characteristics, disease history, clinical features, prior treatments, current treatment patterns, clinical outcomes, and patient-reported outcomes (PROs). The objective is to describe the disease profile, current diagnostic and therapeutic landscape, clinical progression, and prognosis of this specific patient population in China. The data generated will provide a foundational basis for deepening the understanding of disease progression, identifying unmet clinical needs, and exploring potential surrogate endpoints for future clinical trials in drug development. The study plans to enroll 10 eligible patients with BCL-2-associated athanogene 3 (BAG3)-associated inherited DCM from 3 research sites across China.",[26],[117],"BAG3 ; Dilated cardiomyopathy; Observational Cohort Study","NOT_YET_RECRUITING","2026-06-09",{"date":121,"type":33},"2026-06-15",{"date":123,"type":20},"2026-06-29",{"date":125,"type":20},"2029-06-29",{"name":69,"class":70},{"id":128,"slug":129,"hasResults":11,"nctId":130,"briefTitle":131,"officialTitle":132,"acronym":133,"eligibilityCriteria":134,"healthyVolunteers":135,"sex":15,"minAge":50,"maxAge":4,"enrollmentInfo":136,"targetDuration":4,"studyType":80,"phases":4,"briefSummary":138,"conditions":139,"keywords":154,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":169,"lastUpdatePostDateStruct":170,"startDateStruct":172,"completionDateStruct":174,"leadSponsor":176,"locationsCount":178},"100569808","ai-enabled-direct-from-ecg-ejection-fraction-ef-severity-assessment-using-cor-ecg-wearable-monitor-100569808","NCT06699056","AI-Enabled Direct-from-ECG Ejection Fraction (EF) Severity Assessment Using COR ECG Wearable Monitor","AI-Enabled Direct-from-ECG Ejection Fraction (EF) Severity Using COR ECG Wearable Monitor","EFACT","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Able and eligible to wear a Holter monitor\n\nExclusion Criteria:\n\n* Receiving mechanical respiratory or circulatory support, or renal support therapy, at the time of screening or during Visit #1\n* Any condition that, in the investigator's opinion, could interfere with compliance with the study protocol or pose a safety risk to the participant\n* History of poor tolerance or severe skin reactions to ECG adhesive materials",true,{"count":137,"type":20},2000,"This prospective, multicenter, cluster-randomized controlled study aims to evaluate the accuracy of an investigational artificial intelligence (AI) Software as a Medical Device (SaMD) designed to compute ejection fraction (EF) severity categories based on the American Society of Echocardiography's (ASE) 4-category scale. The software analyzes continuous ECG waveform data acquired by the FDA-cleared Peerbridge COR® ECG Wearable Monitor, an ambulatory patch device designed for use during daily activities. The AI software assists clinicians in cardiac evaluations by estimating EF severity, which reflects how well the heart pumps blood.\n\nIn this study, EF severity determination will be made using 5-minute ECG recordings collected during a 15-minute resting period with participants seated upright. The results will be compared to EF severity obtained from an FDA-cleared, non-contrast transthoracic echocardiogram (TTE) predicate device. This comparison aims to validate the accuracy of the AI software.",[140,141,142,143,144,145,146,147,148,149,26,150,151,152,153],"Ventricular Ejection Fraction","LVF","LV Dysfunction","Atrial Enlargement","Conduction Defect","Heart Failure","Valvular Heart Disease","Ischemic Heart Disease","Cardiotoxicity","Myocardial Infarction","HFrEF - Heart Failure With Reduced Ejection Fraction","HFpEF - Heart Failure With Preserved Ejection Fraction","Syncope","Remodeling, Cardiac",[155,156,157,158,159,160,161,142,162,163,164,165,166,167,143,168],"ECG Patch","LVEF","Holter","ECG Wearable","COR","Atrial Conduction","ECG Biomarker","SaMD","Clinical Decision Support","ECG","EF Severity","Ejection Fraction","AI","Electrical Remodeling","2026-05-28",{"date":171,"type":33},"2026-06-01",{"date":173,"type":33},"2024-11-21",{"date":175,"type":20},"2027-11-15",{"name":177,"class":70},"Peerbridge Health, Inc",8,{"id":180,"slug":181,"hasResults":11,"nctId":182,"briefTitle":183,"officialTitle":184,"acronym":185,"eligibilityCriteria":186,"healthyVolunteers":11,"sex":15,"minAge":50,"maxAge":4,"enrollmentInfo":187,"targetDuration":189,"studyType":80,"phases":4,"briefSummary":190,"conditions":191,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":202,"lastUpdatePostDateStruct":203,"startDateStruct":205,"completionDateStruct":207,"leadSponsor":209,"locationsCount":104},"100625305","study-of-the-progression-of-chronic-cardiovascular-conditions-100625305","NCT07420907","Study of the Progression of Chronic Cardiovascular Conditions","A Non-interventional Observational Study of the Sustained Use of Prolaio Digital Health Devices to Monitor the Natural History of Chronic Cardiovascular Conditions in Ambulatory Patients","OCORO","Inclusion Criteria:\n\n* 18 years of age and older\n* Ability to understand study assessments and give informed consent to data collection\n* Ability to comply with the study protocol\n* Ability to understand and respond to instructions in English\n* Has diagnosis of qualifying Cardiovascular Disease(s) (CVD) including but not limited to: HF, AS, HCM, HTN, DCM, etc.\n* Resides in the United States\n\nExclusion Criteria:\n\n* Allergy to adhesive used in biosensor patch\n* Life threatening disease process outside of area under study, such as actively treated cancer or pre\u002Fpost-transplant such as hepatic failure; end-stage renal disease.\n* Severe CVD defined by hospital admission for cardiac diagnosis within 30 days of enrollment or documentation of NYHA functional class IV\n* Self-reported weight of 400 pounds or greater",{"count":188,"type":20},5000,"5 Years","This study will collect physiologic data in patients with cardiovascular conditions and observe the natural history of those conditions for research purposes.",[192,145,193,194,195,196,197,198,199,200,26,201],"Cardiovascular Disease (CVD)","Aortic Stenosis","Aortic Stenosis Disease","Hypertension","Hypertension (HTN)","Hypertrophic Cardiomyopathy Patients","Hypertrophic Cardiomyopathy Without Obstruction","Hypertrophic Cardiomyopathy, Obstructive","Dilated Cardiomyopathy (DCM)","Dilated Cardiomyopathy, Familial","2026-02-16",{"date":204,"type":33},"2026-02-19",{"date":206,"type":33},"2025-10-30",{"date":208,"type":20},"2030-10",{"name":210,"class":70},"Prolaio",{"id":212,"slug":213,"hasResults":11,"nctId":214,"briefTitle":215,"officialTitle":215,"acronym":216,"eligibilityCriteria":217,"healthyVolunteers":11,"sex":15,"minAge":50,"maxAge":4,"enrollmentInfo":218,"targetDuration":4,"studyType":80,"phases":4,"briefSummary":220,"conditions":221,"keywords":224,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":227,"lastUpdatePostDateStruct":228,"startDateStruct":230,"completionDateStruct":232,"leadSponsor":234,"locationsCount":104},"100482642","absolute-coronary-flow-in-patients-with-heart-failure-with-reduced-ejection-fraction-and-left-bundle-branch-block-with-cardiac-resynchronization-therapy-100482642","NCT05564689","Absolute Coronary Flow in Patients With Heart Failure With Reduced Ejection Fraction and Left Bundle Branch Block With Cardiac Resynchronization Therapy","FLOW-LBBB","Inclusion Criteria:\n\n* Age \\> 18\n* QRS ≥ 150 ms before implantation\n* Heart failure because of dilated cardiomypathy\n* Sinus rhythm\n* Stable medical therapy\n* LBBB\n* CRT device\n\nExclusion Criteria:\n\n* eGFR \\\u003C 30 ml\u002Fmin\n* Severe valvular heart disease\n* Permanent atrial fibrillation or atrial flutter\n* Prior PCI or CABG\n* Prior myocardial infarction\n* Heart failure due to ischemic heart disease\n* Other type of device (pacemaker, ICD)\n* Not able to give informed consent\n* Does not understand Danish",{"count":219,"type":20},60,"Cardiac resynchronization therapy (CRT) is an effective therapeutic strategy in patients with symptomatic heart failure (HF) patients with LVEF of ≤35% and left bundle branch block (LBBB). However, approximately one-third of CRT-recipients do not improve after therapy (non-responders), despite meeting the required criteria.\n\nPrevious studies have documented that the positive respons to CRT is related to the delayed electrical activation of the left ventricle in patients with LBBB. It has also been illustrated that non-ischemic CRT-candidates with LBBB demonstrate lower regional myocardial blood flow and metabolism in the septum. Additionally, it has been suggested that LBBB can lead to impaired coronary blood flow in the left anterior descending artery (LAD). This observation is based on an echocardiography-based study, that showed that the percentage of diastolic flow duration (%DD) in LAD was shorter in patients with LBBB compared to the control-group and patients with right-ventricular pacing.\n\nIt has been demonstrated that CRT has positive effects on septal myocardial perfusion in patients with HF and LBBB. The dominant hypothesis explaining this phenomenon is built on improved septal myocardial work after CRT-implantation, which leads to increased myocardial energy and therefore increased myocardial perfusion. In contrast, it has been suggested that due to re-established synchronous left ventricular electrical activation, CRT reduces the septal intramyocardial pressure in early diastole, leading to a relatively longer antegrade flow duration in LAD. Therefore, the aim of the study is to evaluate the effect of CRT on coronary blood flow in LAD in patients with non-ischemic HF and LBBB.\n\nThe investigators hypothesize that increased LV-function after CRT not only is due to resynchronized LV ejection and filling, but also improved coronary flow.\n\nThe study aims to enroll 60 patients with heart failure due to non-ischemic dilated cardiomyopathy, LBBB, with or without CRT. All patients meeting the criteria will be recruited from the outpatient clinic at the Department of Cardiology, Aalborg University Hospital.\n\nInvasive flow measurements in the LAD, including fractional flow reserve (FFR), absolute coronary flow and -reserve will be conducted with the CRT on and off, respectively.",[222,145,223,26],"Left Bundle-Branch Block","Cardiac Resynchronization Therapy",[225,226],"absolute coronary flow","fractional flow reserve","2025-06-16",{"date":229,"type":33},"2025-06-18",{"date":231,"type":33},"2022-09-29",{"date":233,"type":20},"2026-09-30",{"name":235,"class":40},"Ashkan Eftekhari",{"id":237,"slug":238,"hasResults":11,"nctId":239,"briefTitle":240,"officialTitle":241,"acronym":242,"eligibilityCriteria":243,"healthyVolunteers":11,"sex":15,"minAge":244,"maxAge":4,"enrollmentInfo":245,"targetDuration":4,"studyType":80,"phases":4,"briefSummary":247,"conditions":248,"keywords":264,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":274,"lastUpdatePostDateStruct":275,"startDateStruct":277,"completionDateStruct":279,"leadSponsor":281,"locationsCount":283},"100578603","characterization-of-patients-with-cardiomyopathy-to-identify-critical-patients-candidates-for-cardiac-transplantation-100578603","NCT06813443","Characterization of Patients With Cardiomyopathy to Identify Critical Patients Candidates for Cardiac Transplantation","Clinical, Instrumental, and Molecular (Circulating and Tissue microRNAs) Characterization of Patients With Cardiomyopathy to Identify Critical Patients With Severe Organ Failure to be Candidates for Cardiac Transplantation","CMPMIRNA","Inclusion Criteria:\n\n* Patients diagnosed with CMP according to current international guidelines\n* Age ≥ 12 years at the time of diagnosis\n* Obtaining informed consent from the patient and the parent or legal guardian (in the case of patients aged \\\u003C 18 years)\n\nExclusion Criteria:\n\n* none","12 Years",{"count":246,"type":20},700,"The study aims to identify new diagnostic and prognostic markers for CMP that can help predict disease progression. In particular, the study will focus on microRNAs (miRNAs) and spatial transcriptomics, which are emerging techniques that may provide insights into the underlying disease mechanisms. By understanding these markers, the investigators hope to improve the way the investigators diagnose and manage CMP, particularly in terms of predicting progression to heart failure or heart transplantation.\n\nThe study will evaluate patients with hypertrophic cardiomyopathy (e.g., sarcomeric forms, Anderson-Fabry disease, AL, and TTR cardiac amyloidosis), dilated cardiomyopathy and arrhythmogenic cardiomyopathy. These patients will undergo clinical evaluations, including ECG, echocardiograms, CMR, biopsy analysis, and genetic testing, as well as molecular studies such as transcriptomics and miRNA analysis. This comprehensive approach aims to identify potential new biomarkers for diagnosing and predicting the disease course.",[83,249,250,251,252,253,254,255,26,256,257,258,259,260,261,262,263],"Amyloidosis Cardiac","Fabry Disease","Arrhythmogenic Cardiomyopathy","Hypertrophic Cardiomyopathy (HCM)","Laminopathies","Dystrophia Myotonica","Mitochondrial Cardiomyopathy","Sudden Cardiac Death","Heart Transplantation","Glycogen Storage Disease","Infiltrative Cardiomyopathy","Cardiac Magnetic Resonance Imaging","Electrocardiogram","Micro RNA","Echocardiogram",[265,266,267,268,269,270,271,272,273],"cardiomyopathy","cardiac amyloidosis","Fabry disease","hypertrophic cardiomyopathy","dilated cardiomyopathy","sudden cardiac death","arrhythmogenic cardiomyopathy","heart failure","heart transplantation","2025-02-03",{"date":276,"type":33},"2025-02-07",{"date":278,"type":33},"2023-02-13",{"date":280,"type":20},"2027-12-14",{"name":282,"class":40},"IRCCS Azienda Ospedaliero-Universitaria di Bologna",3,{"id":285,"slug":286,"hasResults":11,"nctId":287,"briefTitle":288,"officialTitle":289,"acronym":290,"eligibilityCriteria":291,"healthyVolunteers":135,"sex":15,"minAge":50,"maxAge":4,"enrollmentInfo":292,"targetDuration":4,"studyType":21,"phases":294,"briefSummary":296,"conditions":297,"keywords":299,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":300,"lastUpdatePostDateStruct":301,"startDateStruct":303,"completionDateStruct":305,"leadSponsor":307,"locationsCount":104},"100568988","dilated-cardiomyopathy-detection-using-ai-and-screening-with-mobile-technology-dcm-detect-100568988","NCT06688396","Dilated Cardiomyopathy Detection Using AI and Screening With Mobile Technology (DCM-DETECT)","Dilated Cardiomyopathy Detection Using Artificial Intelligence and Screening With Mobile Technology","DCM-DETECT","Inclusion Criteria (Proband)\n\n* Male or female age ≥ 18 years\n* Confirmed diagnosis of non-ischemic DCM determined at the discretion of the treating physician and defined as LVEF ≤ 45% at any time during the clinical course of the patient\n* Must have at least one living adult FDR\n* Able to provide informed consent\n\nInclusion Criteria (FDR)\n\n* Male or female age ≥ 18 years who are first-degree relatives of patients with DCM\n* Proband has provided informed consent\n* FDR able to provide informed verbal consent\n* Access to a smartphone or digital tablet with cellular data or Wi-Fi access\n\nExclusion Criteria (Proband)\n\n* DCM attributed to any other secondary form of cardiomyopathy per the investigator's determination\n* Proband has previously informed FDR to undergo cardiac screening\n* Ischemic cause of reduced LVEF\n\n  * evidence of myocardial infarction, inducible ischemia or chest pain on stress testing in absence of coronary angiogram to rule out ischemic disease\n  * history of acute coronary syndromes (STEMI (ST-Elevation Myocardial Infarction), NSTEMI (Non-ST-Elevation Myocardial Infarction) or unstable angina) revascularization or ≥75% stenosis of either left main or Left Anterior Descending (LAD) or ≥75% stenosis of 2 major epicardial vessels on angiogram\n* Moderate or greater primary valvular abnormality not due to underlying cardiomyopathy\n* Congenital structural heart disease\n* Severe and untreated or untreatable hypertension\n* Cardiomyopathy due to acute or reversible conditions; examples include tachyarrhythmias, thyroid disorders, iron overload\n* Any secondary cause of reduced LVEF such as pregnancy, myocarditis, amyloidosis, sarcoidosis, exposure to toxins including alcohol, substance abuse or chemotherapeutic drug\n* (CPC Participants only) Home address outside of traveling range\n\nExclusion Criteria (FDR)\n\n* Previously informed about cardiac screening or has completed cardiac screening by transthoracic echocardiogram (TTE)\n* Previously diagnosed with reduced LVEF\n* (CPC Participants only) Home address outside of traveling range",{"count":293,"type":20},150,[295],"NA","This is a prospective, single-arm clinical trial in which participants with dilated cardiomyopathy will invite their first degree relatives to undergo mobile cardiac, electrocardiogram screening.",[26,145,298],"Heart Disease",[26,145,298],"2025-01-28",{"date":302,"type":33},"2025-01-30",{"date":304,"type":33},"2024-12-04",{"date":306,"type":20},"2026-12",{"name":308,"class":40},"Lancaster General Hospital",{"id":310,"slug":311,"hasResults":11,"nctId":312,"briefTitle":313,"officialTitle":314,"acronym":315,"eligibilityCriteria":316,"healthyVolunteers":11,"sex":15,"minAge":50,"maxAge":4,"enrollmentInfo":317,"targetDuration":319,"studyType":80,"phases":4,"briefSummary":320,"conditions":321,"keywords":324,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":329,"lastUpdatePostDateStruct":330,"startDateStruct":332,"completionDateStruct":334,"leadSponsor":336,"locationsCount":71},"100572222","image-based-prediction-of-ventricular-tachycardia-events-in-non-ischemic-cardiomyopathy-100572222","NCT06730464","Image-Based Prediction of Ventricular Tachycardia Events in Non-ischemic Cardiomyopathy","Image-Based Prediction of Ventricular Tachycardia Events in Non-ischemic Cardiomyopathy, an International Multicenter Study - [The IMPROVE-NICM Study]","IMPROVE-NICM","Inclusion Criteria:\n\n* Diagnosis of non-ischemic heart disease involving the left ventricle, irrespectively of LVEF. This diagnosis includes:\n\n  1. Dilated cardiomyopathy (DCM)\n  2. Non-dilated left ventricular cardiomyopathy (NDLVC)\n  3. Post-myocarditis cardiomyopathy\n* Life expectancy of \\> 1 year with a good functional status.\n* Signed informed consent.\n* At least one late gadolinium enhancement-cardiac magnetic resonance (LGE-CMR) already performed.\n* No VA events at the time of the 1st LGE-CMR study.\n\nExclusion Criteria:\n\n* Pregnancy.\n* Life expectancy of \\\u003C 1 year, or bad functional status (NYHA IV functional class).\n* Other concomitant structural heart diseases (e.g. ischemic, congenital, arrhythmogenic right ventricular cardiomyopathy etc.)\n* No LGE-CMR at time of enrollment or LGE-CMR data not available.\n* Previously documented sustained ventricular arrhythmias at the time of 1st LGE-CMR.\n* Concomitant investigation treatments.\n* Medical, geographical and social factors that make study participation impractical, and inability to give written informed consent. Patient's refusal to participate in the study.",{"count":318,"type":20},500,"2 Years","Risk stratification for sudden cardiac death (SCD) in patients with non-ischemic cardiomyopathy (NICM) remains suboptimal. Although current guidelines rely on severe left ventricular systolic dysfunction (left ventricular ejection fraction (LVEF) \\\u003C 35%) as key predictor of arrhythmic risk and clinical indication of prophylactic implantable cardioverter defibrillator (ICD), this approach seems inadequate, since registries report that only a minority of NICM ICD carriers experience an appropriate ICD shock during follow-up, whereas out-of-hospital cardiac arrests (OHCA) occur in patients with LVEF\\>35% in up to 80% of cases. Moreover, pivotal primary prevention trials (DANISH trial, long-term outcome of the SCD-HeFT trial) failed to demonstrate a net mortality benefit of ICD in patients with NICM.\n\nAs for most structural heart diseases (SHD), scar-related reentry has been addressed as the pathophysiological mechanism of ventricular arrhythmias (VAs) in patients with NICM, with fibrotic tissue being the substrate of this reentry. Late gadolinium enhancement cardiac magnetic resonance (LGE-CMR) is the gold standard for the non-invasive visualization and characterization of the myocardial fibrosis and according to retrospective studies is detected in nearly 30% of patients with NICM.\n\nIn latest years, several studies and subsequent metanalyses have explored the correlation between CMR-detected LGE and occurrence of VAs, showing that presence, extent, location (septal vs lateral) and patten (focal vs multifocal vs ring-like) of non-ischemic fibrosis help in stratifying arrhythmic risk.\n\nNonetheless, scar heterogeneity (that is, inherent composition of dense scars vs border zone (BZ), presence of strands of viable myocardium within the scar) has been indicated as a potential novel predictor of VAs. In a recent prospective multicenter registry on patients with class I indication for cardiac resynchronization therapy (CRT) (\\>60% with NICM), not only scar mass, but even border zone (BZ) mass and presence of BZ channels were identified as independent predictors for VT occurrence in NICM patients.\n\nThis BZ mass and BZ channels can be automatically identified using a commercially available, post-processing imaging platform named ADAS 3D LV (ADAS3D Medical SL, Barcelona, Spain), with FDA 510(k) Clearance and CE Mark approval. Thus, CMR-derived BZ mass might be used as an automatically reproducible criterium to reclassify those patients with NICM at highest risk for developing VAs\u002FSCD in a relatively short period of at least 2 years.\n\nIn the present cohort study, the investigators sought to: i) evaluate the usefulness of CMR-derived BZ mass measurement and identification of heterogeneous tissue channels (HTC) (among other scar characteristics derived from image post-processing) to predict the occurrence of VT events in an international, retrospective, multicenter, unselected series of patients with NICM without previous arrhythmia evidence (main study); ii) subsequently validate these predictors of VT occurrence in a prospectively-collected multicenter cohort study (substudy 1); iii) retrospectively evaluate in the subset of patients with \\> 1 LGE-CMR performed as part of standard clinical practice if any change in BZ mass and HTC presence occurs over time and if this correlates with occurrence of VAs (substudy 2).",[26,251,322,323],"Ventricular Arrhythmia","Hypertrophic Cardiomyopathies",[325,326,327,328],"Dilated cardiomyopathy","Non-dilated left ventricular cardiomyopathy (NDLVC)","border zone channels","ventricular arrhythmias","2024-12-08",{"date":331,"type":33},"2024-12-12",{"date":333,"type":33},"2024-10-07",{"date":335,"type":20},"2027-02-23",{"name":337,"class":40},"Centro Medico Teknon",{"id":339,"slug":340,"hasResults":11,"nctId":341,"briefTitle":342,"officialTitle":343,"acronym":4,"eligibilityCriteria":344,"healthyVolunteers":11,"sex":345,"minAge":50,"maxAge":346,"enrollmentInfo":347,"targetDuration":4,"studyType":21,"phases":349,"briefSummary":351,"conditions":352,"keywords":353,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":363,"lastUpdatePostDateStruct":364,"startDateStruct":366,"completionDateStruct":368,"leadSponsor":370,"locationsCount":104},"100535317","phase-3-bromocriptine-in-dilated-cardiomyopathy-among-women-of-reproductive-age-100535317","NCT06250257","Bromocriptine in Dilated Cardiomyopathy Among Women of Reproductive Age","Effect of Bromocriptine in Dilated Cardiomyopathy in Women of Reproductive Age: A Hospital-Based Randomized Open Label Placebo-controlled Clinical Trial","Inclusion Criteria:\n\n* Women age 18 years to 50 years and\n* ischemic or de novo dilated cardiomyopathy\n\nExclusion Criteria:\n\n* Patients with severe comorbidities which may worsen their illness\n* with hypertensive heart diseases\n* Rheumatic valvular heart diseases\n* Restrictive cardiomyopathy, constrictive cardiomyopathy, hypertrophic cardiomyopathy\n* Congenital heart diseases\n* Acute coronary syndrome\n* Overt kidney failure (serum Creatinine ≥ 1.4mg\u002Fdl),\n* Women who had history of peripartal cardiomyopathy, are pregnant or planning pregnancy during the study period or lactating\n* Previous adverse reaction to the bromocriptine\n* Patients not willing to participate in the study","FEMALE","50 Years",{"count":348,"type":20},112,[350],"PHASE3","Dilated cardiomyopathy (DCM) is a condition associated with left and \u002For right ventricular (LV) dilatation and systolic dysfunction without coronary artery disease or abnormal loading circumstances proportionate to the severity of LV impairment. It is one of the leading causes of heart failure in younger adults. About 35% of patients have genetic mutations affecting cytoskeletal, sarcomere, and nuclear envelope proteins while others are idiopathic and possibly complications of myocarditis. Recently, in patients with peripartum cardiomyopathy (PPCM)-a subtype of dilated cardiomyopathy, high levels of prolactin and its degradation by-products including a cleaved 16kDa N-terminal fragment have emerged as key factors in the pathophysiology. The 16kDa prolactin induces profound endothelial damage and subsequent cardiomyocyte dysfunction and hence heart failure. Bromocriptine has been studied as a potential treatment option and placebo-controlled studies have demonstrated its beneficial role in women with Peripartal cardiomyopathy (PPCM). However, prolactin level may also increase during menstrual cycles of reproductive-age women, which candidates the use of bromocriptine in women of all reproductive ages. The aim of this study is therefore to assess the potential effect of bromocriptine in dilated cardiomyopathy among women of reproductive age.",[26],[269,354,355,356,357,358,359,360,361,362],"left ventricular function","ejection fraction","prolactin","bromocriptine","cardiac biomarkers","quality of life","Exercise capacity","6-minute walk test","Standard stair climbing test","2024-11-16",{"date":365,"type":33},"2024-11-19",{"date":367,"type":33},"2024-10-21",{"date":369,"type":20},"2026-11-30",{"name":371,"class":40},"Jimma University",{"id":373,"slug":374,"hasResults":11,"nctId":375,"briefTitle":376,"officialTitle":376,"acronym":4,"eligibilityCriteria":377,"healthyVolunteers":135,"sex":15,"minAge":50,"maxAge":4,"enrollmentInfo":378,"targetDuration":4,"studyType":80,"phases":4,"briefSummary":380,"conditions":381,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":389,"lastUpdatePostDateStruct":390,"startDateStruct":392,"completionDateStruct":394,"leadSponsor":396,"locationsCount":104},"100398171","a-10-minute-cardiovascular-magnetic-resonance-protocol-for-cardiac-disease-100398171","NCT04464655","A 10-Minute Cardiovascular Magnetic Resonance Protocol for Cardiac Disease","Healthy Volunteers\n\nInclusion Criteria:\n\n* Age: \\> 18y, Informed consent No known current or pre-existing significant medical conditions that would affect the cardiovascular or respiratory system\n\nExclusion Criteria:\n\n* General MRI contraindications: MR- incompatible devices such as pacemakers, defibrillators, or implanted material or foreign bodies. Consumption of caffeinated drinks or foods (including cocoa and chocolate) during the 12 hours prior to the exam.Regular nicotine consumption during the last 6 months\n\nPatients\n\nInclusion Criteria:\n\n* Age: \\>18 y, Informed consent, Clinically indicated CMR exam\n\nExclusion Criteria:\n\n* General MRI contraindications: MR- incompatible devices such as pacemakers, defibrillators, or implanted material or foreign bodies Vasoactive medication (e.g. nitro) during the 12 hours prior to the exam. Consumption of caffeinated drinks or foods (including cocoa and chocolate) during the 12 hours prior to the exam.\n\nRegular nicotine consumption during the last 6 months",{"count":379,"type":20},2130,"This study aims to identify and assess new CMR techniques that can improve current CMR protocols.",[382,383,259,26,84,384,385,386,387,388],"Coronary Artery Disease","Myocarditis","Aortic Valve Stenosis","Aortic Valve Regurgitation","Pericardial Effusion","Congenital Heart Disease","Vascular Anomaly","2024-10-22",{"date":391,"type":33},"2024-10-24",{"date":393,"type":33},"2019-12-12",{"date":395,"type":20},"2025-01-31",{"name":397,"class":40},"McGill University Health Centre\u002FResearch Institute of the McGill University Health Centre",{"id":399,"slug":400,"hasResults":11,"nctId":401,"briefTitle":402,"officialTitle":403,"acronym":4,"eligibilityCriteria":404,"healthyVolunteers":11,"sex":15,"minAge":405,"maxAge":406,"enrollmentInfo":407,"targetDuration":4,"studyType":21,"phases":409,"briefSummary":411,"conditions":412,"keywords":413,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":414,"lastUpdatePostDateStruct":415,"startDateStruct":417,"completionDateStruct":419,"leadSponsor":421,"locationsCount":104},"100564719","phase-2-outcome-targeted-therapy-principle-and-outcome-evaluation-clinical-study-and-phenotype-genotype-correlation-100564719","NCT06632834","Outcome-targeted Therapy: Principle and Outcome Evaluation: Clinical Study and Phenotype-genotype Correlation","Outcome-targeted Therapy: Principle and Outcome Evaluation: Clinical Study, and Phenotype-genotype Correlation","Inclusion criteria\n\nPatients diagnosed as dilated cardiomyopathy, classified as NYHA functional class II or III and still have a low left ventricular ejection fraction (LVEF) (LVEF \\\u003C 45% and the Z score of the LV end-diastolic diameter \\> 2.0) will be enrolled, if they have normal or high level of cholesterol and triglyceride and fulfill any of the following criteria:\n\n1. Patients who have already received anti-congestive medications for at least three months and still have poor LV function (LVEF \\\u003C 45% and the Z score of the LV end-diastolic diameter \\> 2.0).\n2. Patients who have persistent or even worsening heart failure after one month of anti-congestive medications.\n3. Patients who have positive family history of dilated cardiomyopathy and have received anti-congestive medications for one month.\n4. Patients or their parents must sign an informed consent form.\n\nExclusion criteria\n\nPatients who fulfill any of the following criteria will be excluded from the trial:\n\n1. Patients who underwent prior cardiac surgery. Those who received DCM related surgery, such as mitral valve plasy, for longer than a year are not subject to this restriction.\n2. Patients who had active liver \u002F renal dysfunction.\n3. Concomitant use with gemfibrozil, cyclosporine, danazol, strong CYP3A4 inhibitors (eg, boceprevir, clarithromycin, erythromycin, HIV protease inhibitors, itraconazole, ketoconazole, nefazodone, posaconazole, telaprevir, telithromycin, voriconazole), or cobicistat-containing products\n4. Patients who are pregnant or plan to pregnancy in the period of study.\n5. Patients who are intolerance to simvastatin therapy.","0 Years","99 Years",{"count":408,"type":20},230,[410],"PHASE2","Brief Summary(Use lay language. Include a statement of the study hypothesis.):\n\nDilated cardiomyopathy (DCM) is the most common childhood cardiomyopathy and is associated with significant early morbidity and mortality. Those who fail to improve within the first year of diagnosis usually deteriorated even upon aggressive anti-congestive medications. Investigators had conducted precision-medicine-based approach to provide strategic approach as drug repurposing to identify new treatments. Investigators have identified the beneficial effects from a statin, simvastatin, to restore the cardiac contractility in the human induced pluripotent stem cell lines derived from a DCM proband and the proband's father. The mutant mouse consequently confirmed the beneficial effects. The initial experience in the proband is promising. This clinical trial is to find out if simvastatin will benefit the cardiac function of DCM patients.",[26],[265],"2024-10-13",{"date":416,"type":33},"2024-10-16",{"date":418,"type":33},"2020-08-15",{"date":420,"type":20},"2025-01-19",{"name":422,"class":40},"National Taiwan University Hospital",{"id":424,"slug":425,"hasResults":11,"nctId":426,"briefTitle":427,"officialTitle":428,"acronym":429,"eligibilityCriteria":430,"healthyVolunteers":11,"sex":15,"minAge":4,"maxAge":4,"enrollmentInfo":431,"targetDuration":4,"studyType":80,"phases":4,"briefSummary":433,"conditions":434,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":435,"lastUpdatePostDateStruct":436,"startDateStruct":438,"completionDateStruct":440,"leadSponsor":442,"locationsCount":444},"100496892","the-smarter-cardiomyopathy-study-100496892","NCT05750147","The SMARTER Cardiomyopathy Study","Genetics, Imaging and Artificial Intelligence for Precision Care in Cardiomyopathy","SMARTER-CM","Inclusion Criteria:\n\nAdults with the capacity to consent Children with parental\u002Fguardian consent Male and Female\n\nMeeting the following criteria:\n\n1. Patients with a confirmed diagnosis of cardiomyopathy or related condition\n2. Patients with a family member with cardiomyopathy, or a related condition\n3. Patients with a genetic variant that may predispose to cardiomyopathy, or a related condition\n\nExclusion Criteria:\n\nPatients without the capacity to provide informed consent",{"count":432,"type":20},1000,"Cardiomyopathies are diseases of the heart muscle. Known genetic factors may account for some cardiomyopathy cases but there is still much to understand about the genetic and environmental causes and how the disease progresses.\n\nFinding new ways to diagnose and treat cardiomyopathies could improve the health and well-being of patients with these conditions.\n\nThis study will collect data from individuals with cardiomyopathy or related heart muscle disease, or with a possible genetic predisposition to cardiomyopathy, and follow them over time to observe the progress of their heart and health. This study will collect DNA, blood samples, and detailed clinical \\& lifestyle information at the start of the study, and data collected during routine healthcare visits over time.\n\n* learn what causes cardiomyopathy, and therefore how to treat it\n* understand why cardiomyopathy progresses differently in different people, to improve the ability to recognise who will benefit from different treatments at different times\n\nThe investigators will collaborate with other centres internationally to collect a large of group of participants with similar cardiomyopathies, providing power to identify new pathways that cause disease and ways of predicting which participants are at risk of having more severe disease.",[83,84,26],"2024-03-05",{"date":437,"type":33},"2024-03-06",{"date":439,"type":33},"2023-03-01",{"date":441,"type":20},"2027-08-01",{"name":443,"class":40},"Imperial College London",2,{"id":446,"slug":447,"hasResults":11,"nctId":448,"briefTitle":449,"officialTitle":449,"acronym":450,"eligibilityCriteria":451,"healthyVolunteers":11,"sex":15,"minAge":50,"maxAge":452,"enrollmentInfo":453,"targetDuration":4,"studyType":21,"phases":455,"briefSummary":457,"conditions":458,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":460,"lastUpdatePostDateStruct":461,"startDateStruct":463,"completionDateStruct":465,"leadSponsor":467,"locationsCount":104},"100534222","phase-4-the-effects-of-sirolimus-in-patients-with-dilated-cardiomyopathy-infected-with-kaposi-sarcoma-associated-virus-100534222","NCT06236022","The Effects of Sirolimus in Patients With Dilated Cardiomyopathy Infected With Kaposi Sarcoma-associated Virus","SDCMK","Inclusion Criteria:\n\n* 18 to 70 years of age;\n* Diagnosed as dilated cardiomyopathy. Specifically, (i) left ventricular ejection fraction \\\u003C45% (\\>2 SD) and\u002For fractional shortening \\\u003C25% (\\>2 SD), as ascertained by echocardiography, radionuclide scanning, or cardiac magnetic resonance imaging; (ii) left ventricular end-diastolic diameter \\>117% of the predicted value corrected for age and body surface area (Henry's formula), which corresponds to 2 SD of the predicted normal limit +5%; and (iii) In the absence of severe coronary artery disease or valvular disease.\n* KSHV DNA seropositivity;\n* Patients are voluntary and signed informed consent.\n\nExclusion Criteria:\n\n* Allergic to rapamycin or its derivatives；\n* The proportion of neutrophils less than 0.5\\*10\\^9\u002FL or platelet less than 2.5\\*10\\^10\u002FL;\n* Pregnant women or plan to;\n* Participate in any drug clinical trials within 3 months;\n* Serious neurological disease (Alzheimer's disease, Parkinson syndrome, progressive lower limbs or deaf patients);\n* Previous history of cancer or tumor, or pathological examination confirmed precancerous lesions;\n* Patients were not optimally managed.","70 Years",{"count":454,"type":20},276,[456],"PHASE4","Evaluating the efficacy of sirolimus (compared to standard therapy alone) in the treatment of dilated cardiomyopathy infected with Kaposi Sarcoma-associated virus -- a multicenter randomized controlled study.",[26,459],"Kaposi's Sarcoma-Associated Herpesvirus Infection","2024-01-24",{"date":462,"type":33},"2024-02-01",{"date":464,"type":33},"2024-01-01",{"date":466,"type":20},"2028-12-31",{"name":468,"class":40},"Tongji Hospital",{"id":470,"slug":471,"hasResults":11,"nctId":472,"briefTitle":473,"officialTitle":473,"acronym":4,"eligibilityCriteria":474,"healthyVolunteers":11,"sex":15,"minAge":4,"maxAge":4,"enrollmentInfo":475,"targetDuration":4,"studyType":80,"phases":4,"briefSummary":477,"conditions":478,"keywords":480,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":483,"lastUpdatePostDateStruct":484,"startDateStruct":486,"completionDateStruct":488,"leadSponsor":490,"locationsCount":104},"100438516","cardiac-magnetic-resonance-for-risk-stratification-in-dilated-cardiomyopathy-100438516","NCT04990297","Cardiac Magnetic Resonance for Risk Stratification in Dilated Cardiomyopathy","Inclusion Criteria:\n\n1. reduced left ventricular ejection fraction (LVEF\\\u003C50%)\n2. LV end-diastolic volume \\>2SD from normal according to normograms corrected by body surface area (BSA) and age.\n\nExclusion Criteria:\n\n1. Any evidence indicating the presence of ischemic heart disease:\n\n   Coronary angiography, perfusion imaging Medical documentation that indicated the presence of ischemic heart disease An infarct pattern of late gadolinium enhancement on cardiac magnetic resonance studies and\u002For acute coronary syndrome or coronary revascularization during follow-up\n2. Any evidence of hypertrophic cardiomyopathy, or moderate-to-severe valvular disease\\[18\\], or infiltrative disease (such as amyloidosis, sarcoidosis, Fabry disease)\n3. Incessant arrhythmias\n4. Inability to lie flat\n5. Pregnancy\n6. Contraindication to cardiac magnetic resonance including severe claustrophobia, defibrillators, pacemakers, certain types of intracranial aneurysm clips, intraocular metal, and Stage IV\u002FV chronic kidney disease\n7. Diabetes mellitus with end organ damage\n8. Inability to provide informed consent.",{"count":476,"type":20},2500,"Dilated cardiomyopathy (DCM) is an increasingly recognized cause of morbidity and mortality with heterogenous etiologies (eg, genetic, environment) and clinical manifestations, characterized by left ventricular (LV) systolic dysfunction and LV or biventricular dilation. Previous publications reported the three-year treated mortality rates remain high at 12%-20% and a reported 5-year mortality rate up to 50%, with death resulting from ventricular arrhythmia leading to sudden cardiac death (SCD) or advanced heart failure (HF). With large fields of view and high spatial resolution, Cardiac magnetic resonance (CMR) is the reference standard for assessing cardiac mass, volume, and function. CMR also provides non noninvasive characterization of the myocardium benefiting to differential diagnosis and risk stratification.",[26,479],"Single-center Study",[269,481,482],"cardiovascular magnetic resonance imaging","prognosis","2022-10-27",{"date":485,"type":33},"2022-10-31",{"date":487,"type":33},"2019-12-24",{"date":489,"type":20},"2031-12-31",{"name":491,"class":40},"Chinese Academy of Medical Sciences, Fuwai Hospital",{"id":493,"slug":494,"hasResults":11,"nctId":495,"briefTitle":496,"officialTitle":496,"acronym":497,"eligibilityCriteria":498,"healthyVolunteers":11,"sex":15,"minAge":50,"maxAge":4,"enrollmentInfo":499,"targetDuration":4,"studyType":21,"phases":501,"briefSummary":502,"conditions":503,"keywords":4,"overallStatus":118,"whyStopped":4,"lastUpdateSubmitDate":506,"lastUpdatePostDateStruct":507,"startDateStruct":509,"completionDateStruct":511,"leadSponsor":513,"locationsCount":4},"100362020","cardiovascular-magnetic-resonance-guided-insertion-of-implantable-cardiac-defibrillator-in-dilated-cardiomyopathy-100362020","NCT03993730","Cardiovascular Magnetic Resonance GUIDEd Insertion of Implantable Cardiac Defibrillator in Dilated CardioMyopathy","CMR GUIDE DCM","Inclusion Criteria:\n\n* Age greater than\u002Fequal to 18 years old\n* Non-ischemic cardiomyopathy of dilated type\n* Left Ventricular Ejection Fraction \\\u003C 45%\n* Able and willing to comply with all pre, post and follow-up testing and requirements\n* On maximum tolerated doses of angiotensin converting enzyme (ACE) inhibitors (or Angiotensin Receptor Blockers(ARB) or Neprilysin Inhibitors) and Beta Blockers\n\nExclusion Criteria:\n\n1. Known coronary artery disease (CAD) (History of Myocardial Infarction or Significant Epicardial CAD on Angiography)\n2. Hypertrophic Cardiomyopathy\n3. Cardiomyopathy related to sarcoidosis\n4. Arrhythmogenic Right Ventricular Dysplasia\n5. Standard LGE CMR contraindications (e.g. severe claustrophobia, metal)\n6. Currently implanted permanent pacemaker and\u002For pacemaker\u002FICD lead\n7. Clinical indication for ICD or pacemaker or Cardiac Resynchronisation Therapy\n8. Contraindications to intravenous Gadolinium\n9. Severe renal insufficiency (eGFR\\\u003C 45mls\u002Fmin\u002F1.73m2 )\n10. New York Heart Association Heart Failure functional class IV\n11. Conditions associated with life expectancy \\\u003C1 year\n12. Pregnancy or in females of child-bearing potential, the non-use of accepted forms of contraception",{"count":500,"type":20},1880,[295],"CMR GUIDE DCM is a randomized controlled trial with a registry for non-randomized patients.\n\nPatients enrolled will have non-ischemic cardiomyopathy (NICM) with mild to severe Left Ventricular (LV) systolic dysfunction with replacement fibrosis identified on Cardiac Magnetic Resonance (CMR).\n\n954 patients will be randomised from 50 sites across 4-6 countries worldwide to receive an implantable defibrillator (ICD) or implantable loop recorder (ILR).\n\nDevice and clinical follow-up will be performed at 3, 6, 12, 24, 36 months and at end of study.",[26,504,505],"Left Ventricular Systolic Dysfunction","Fibrosis Myocardial","2019-06-20",{"date":508,"type":33},"2019-06-21",{"date":510,"type":20},"2020-06",{"date":512,"type":20},"2026-06",{"name":514,"class":40},"Flinders University",{"id":516,"slug":517,"hasResults":11,"nctId":518,"briefTitle":519,"officialTitle":519,"acronym":520,"eligibilityCriteria":521,"healthyVolunteers":135,"sex":15,"minAge":522,"maxAge":523,"enrollmentInfo":524,"targetDuration":4,"studyType":80,"phases":4,"briefSummary":525,"conditions":526,"keywords":528,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":533,"lastUpdatePostDateStruct":534,"startDateStruct":536,"completionDateStruct":538,"leadSponsor":540,"locationsCount":104},"100270765","molecular-and-imaging-studies-of-cardiovascular-health-and-disease-100270765","NCT02804269","Molecular and Imaging Studies of Cardiovascular Health and Disease","Biobank","There is no inclusion\u002Fexclusion criteria except for the age limit as this is a repository program.\n\nInclusion Criteria:\n\n•Subject aged ≥ 16 years and ≤ 90 years.\n\nExclusion Criteria:\n\n•No","16 Years","90 Years",{"count":188,"type":20},"Biobank is a program which collects biological samples, health information and imaging data from consented patients and stored them at the core facility. These information would be used to study the molecular, imaging and outcome studies of cardiovascular health and disease.",[527,26,84,147],"Healthy",[529,325,530,531,532],"Healthy Volunteer","Hypertrophic cardiomyopathy","ischemic heart disease","Cardiovascular Magnetic Resonance Imaging","2016-06-14",{"date":535,"type":20},"2016-06-17",{"date":537,"type":4},"2013-07",{"date":539,"type":20},"2033-07",{"name":541,"class":40},"National Heart Centre Singapore"]